JAK1 and neoplasm: Primary and acquired resistance mechanisms remain incompletely understood but include inadequate T-cell tumor infiltration, immunosuppressive tumor microenvironment factors, alternative immune checkpoint expression, JAK1/2 mutations disrupting interferon-gamma signaling, impaired antigen presentation, and neoantigen loss [47–49].